An effective and noninvasive treatment method for primary, reccurent and oligometastatic cancer

Therapy with the robotic radiosurgery CyberKnife M6 is:

  • innovative approach of treatment contrary to the traditional paradigm – surgery, conventional radiotherapy or hormonal therapy (ADT);
  • very precise, fast, effective and safe;
  • do not affect daily life.

The main goals of the therapy are:

  • to find tumour lesions in patient’s body and inactivate them;
  • to prolong symptom-free and overall survival;
  • to preserve the existing quality of life.

Clinical trials confirm:

  • an effective treatment for primary, recurrent or oligometastatic cancer;
  • safety, low toxicity and high local control of metastases;
  • androgen deprivation therapy-free survival (ADT-FS) for 1-3 yrs.
_OBD7468_web

How the therapy works?

Robotic radiosurgery with CyberKnife M6 system is a very precise radiotherapy method, destroying tumour cells with accurately targeted high-dose ionising radiation, which damages DNA of tumour cells, restricting the ability of cells to divide. Cancer cells gradually die and body destroys them naturally. Cancer cells are replaced by inactive cells — connective or scar tissue. This approach enables exposure of the affected tissue while minimising damage and saving the nearby tissue.

advice and second opinion

The primary therapy processes

  • Preparation for treatment sessions using CyberKnife® M6 system are conducted on an outpatient basis at SRC Sigulda.
  • Placement of gold markers in tumor lesions. Low-invasive procedure performed in order to boost the accuracy of the robotic radiosurgery. Performed by urologist or radiation oncologist.
  • Preparatory works and accurate diagnostics with CT and MRI for visualization of prostate cells and cells affected by cancer.
  • Drawing up of final individual treatment plan by using the imaging data to determine locations of the target cells of cancer and critical nearby organs which are then uploaded to CyberKnife® robotic system.
  • Radiosurgery treatment course with system CyberKnife® M6 is performed every day over a course of maximum 5 days, each of them 50 to 60 minutes long.
  • Therapy conclusions (except epicrisis), recommendations for the first three months of the post-treatment period, as well as information about possible side effects.

Follow-up after treatment with CyberKnife® M6:

  • determination of the PSA level in accordance with our doctor’s instructions;
  • consultation (by phone or in an electronic form) on the prevention of side effects, if any;
  • prevention of side effects by medication if necessary.

Continuing treatment with CyberKnife® M6:

  • in case of treatment of a previously treated cancer, and if a recurrence or separate metastases in bones, soft tissue or in other parts are established, robotic radiosurgery with CyberKnife® M6 ensures high control of local recurrence and allows postponing of the hormone replacement therapy and extends symptom free survival;
  • according to recent research results, treatment with CyberKnife M6 can postpone palliative androgen deprivation therapy up to few years without increase PSA level and grade II-III toxicity;
  • if necessary, treatment may be repeated.

SIDE EFFECTS OF THE THERAPY

Most patients, who receive CyberKnife therapy, do not face serious (grade II and III) side effects.

POSSIBLE COMPLICATIONS:

Around 20% of patients developed toxicity following treatment, which was classified as mild (grade I or grade II). In case of bone metastasis irradiation, patients reported mild grade I bone pain.  In case of treatment for nodal metastases some patients experienced grade I fatigue and diarrhoea or worsening of post-radical prostatectomy urinary incontinence.

_OBD7451_web

1. Request the treatment (by phone or in an electronic form) supplemented with your medical information:

      • records of medical history with PSA test dynamics,
      • general clinical and biochemical latest blood test,
      • MRI examination of pelvis, osteoscintigraphy,
      • PET-CT with 18F-PSMA* or 68Ga-PSMA-11* (*prostate-specific membrane antigen) results (not older than 1 months) that confirm accumulation of PSMA in tumour tissues or our doctor will recommend it to do, if there will be necessity.

2. Based on these documents, doctors will make an assessment of your health condition and make the decision on the suitability of the therapy.

Let’s talk?

For a free consultation, call (+371) 67 229 522

or fill in the requested contact details in the application form. Our patient service will get back to you and respond accordingly as soon as possible.

Contact Our Cancer Specialist Today